Sales of the HIV drug Fuzeon dropped in the second quarter of this year, biopharmaceutical firm Trimeris reported Wednesday after the markets closed.

Sales dipped to $62 million from $64.3 million worldwide in the first quarter, even though U.S. and Canadian sales increased, Trimeris (NASDAQ: TRMS) said. The company cited no reason for the dip.

Trimeris works with international pharmaceutical firm Roche to manufacture and sell the drug. The two companies announced earlier this week they planned to pursue a second version of Fuzeon that would require injection once a day rather than twice. The injection method and the need for twice daily injections have been the sources for complaints from many patients.

Global sales of Fuzeon did increase 8 percent in the quarter over the same period in 2006.